procept biorobotics corp - PRCT

PRCT

Close Chg Chg %
20.03 -0.07 -0.35%

Closed Market

19.96

-0.07 (0.35%)

Volume: 773.76K

Last Updated:

Oct 23, 2026, 4:00 PM EDT

Company Overview: procept biorobotics corp - PRCT

PRCT Key Data

Open

$19.90

Day Range

18.75 - 20.12

52 Week Range

16.67 - 38.11

Market Cap

$1.05B

Shares Outstanding

57.27M

Public Float

54.62M

Beta

0.92

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.95

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.35M

 

PRCT Performance

1 Week
 
13.60%
 
1 Month
 
16.05%
 
3 Months
 
19.59%
 
1 Year
 
-42.96%
 
5 Years
 
-53.29%
 

PRCT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About procept biorobotics corp - PRCT

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.

PRCT At a Glance

PROCEPT BioRobotics Corp.
150 Baytech Drive
San Jose, California 95134
Phone 1-650-232-7200 Revenue 308.05M
Industry Medical Specialties Net Income -95,572,000.00
Sector Health Technology 2025 Sales Growth 37.219%
Fiscal Year-end 12 / 2026 Employees 888
View SEC Filings

PRCT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 5.672
Price to Book Ratio 4.843
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -15.794
Enterprise Value to Sales 4.997
Total Debt to Enterprise Value 0.051

PRCT Efficiency

Revenue/Employee 346,907.658
Income Per Employee -107,626.126
Receivables Turnover 3.688
Total Asset Turnover 0.591

PRCT Liquidity

Current Ratio 6.845
Quick Ratio 5.771
Cash Ratio 4.354

PRCT Profitability

Gross Margin 63.699
Operating Margin -33.715
Pretax Margin -30.963
Net Margin -31.024
Return on Assets -18.342
Return on Equity -24.886
Return on Total Capital -21.508
Return on Invested Capital -20.716

PRCT Capital Structure

Total Debt to Total Equity 21.451
Total Debt to Total Capital 17.662
Total Debt to Total Assets 15.447
Long-Term Debt to Equity 20.846
Long-Term Debt to Total Capital 17.164
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Procept Biorobotics Corp - PRCT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
75.01M 136.19M 224.50M 308.05M
Sales Growth
+117.60% +81.55% +64.84% +37.22%
Cost of Goods Sold (COGS) incl D&A
37.93M 65.14M 87.40M 111.83M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.32M 3.81M 5.23M 6.39M
Depreciation
4.02M 3.51M 4.93M 6.09M
Amortization of Intangibles
300.00K 300.00K 300.00K 300.00K
COGS Growth
+103.83% +71.75% +34.17% +27.95%
Gross Income
37.09M 71.05M 137.10M 196.23M
Gross Income Growth
+133.75% +91.58% +92.96% +43.13%
Gross Profit Margin
+49.44% +52.17% +61.07% +63.70%
2022 2023 2024 2025 5-year trend
SG&A Expense
117.81M 180.22M 233.71M 300.08M
Research & Development
28.98M 48.45M 62.30M 71.28M
Other SG&A
88.83M 131.77M 171.41M 228.81M
SGA Growth
+68.23% +52.98% +29.68% +28.40%
Other Operating Expense
- - - -
-
Unusual Expense
- 3.54M 107.00K 114.00K
EBIT after Unusual Expense
(84.27M) (109.28M) (96.73M) (103.86M)
Non Operating Income/Expense
2.29M 7.38M 9.50M 12.06M
Non-Operating Interest Income
2.50M 7.55M 10.89M 12.22M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
5.18M 4.00M 4.18M 3.59M
Interest Expense Growth
-10.79% -22.92% +4.73% -14.29%
Gross Interest Expense
5.18M 4.00M 4.18M 3.59M
Interest Capitalized
- - - -
-
Pretax Income
(87.15M) (105.90M) (91.41M) (95.38M)
Pretax Income Growth
-45.61% -21.51% +13.68% -4.34%
Pretax Margin
-116.18% -77.76% -40.72% -30.96%
Income Tax
- - - 190.00K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - 190.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(87.15M) (105.90M) (91.41M) (95.57M)
Minority Interest Expense
- - - -
-
Net Income
(87.15M) (105.90M) (91.41M) (95.57M)
Net Income Growth
-45.61% -21.51% +13.68% -4.55%
Net Margin Growth
-116.18% -77.76% -40.72% -31.02%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(87.15M) (105.90M) (91.41M) (95.57M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(87.15M) (105.90M) (91.41M) (95.57M)
EPS (Basic)
-1.9629 -2.241 -1.7537 -1.7206
EPS (Basic) Growth
-43.24% -14.17% +21.74% +1.89%
Basic Shares Outstanding
44.40M 47.26M 52.13M 55.54M
EPS (Diluted)
-1.9629 -2.241 -1.7537 -1.7206
EPS (Diluted) Growth
-43.24% -14.17% +21.74% +1.89%
Diluted Shares Outstanding
44.40M 47.26M 52.13M 55.54M
EBITDA
(76.41M) (105.36M) (91.38M) (97.47M)
EBITDA Growth
-49.27% -37.90% +13.27% -6.66%
EBITDA Margin
-101.85% -77.36% -40.70% -31.64%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 22.25
Number of Ratings 15 Current Quarters Estimate -0.246
FY Report Date 12 / 2026 Current Year's Estimate -1.672
Last Quarter’s Earnings -0.39 Median PE on CY Estimate N/A
Year Ago Earnings -1.72 Next Fiscal Year Estimate -1.152
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 11 15 15
Mean Estimate -0.25 -0.39 -1.67 -1.15
High Estimates -0.19 -0.28 -1.60 -0.82
Low Estimate -0.29 -0.53 -1.82 -1.53
Coefficient of Variance -11.26 -18.71 -3.15 -16.70

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 6
OVERWEIGHT 1 0 0
HOLD 9 9 8
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Hold Overweight

Insider Actions for Procept Biorobotics Corp - PRCT

Date Name Shares Transaction Value
Oct 6, 2026 Michael Joseph Mack Director 7,727 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 6, 2026 Michael Joseph Mack Director 12,191 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2026 Alaleh Nouri EVP, CLO, CORP. SEC. 111,166 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $25.6 per share 2,845,849.60
Mar 13, 2026 Alaleh Nouri EVP, CLO, CORP. SEC. 111,021 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $26.74 per share 2,968,701.54

Procept Biorobotics Corp in the News